Spectrum Pharma says ‘lucanthone’ could treat lung cancer
Biopharmaceutical company Spectrum Pharmaceuticals, Inc., (Nasdaq:SPPI) said this morning that preclinical data on lucanthone suggest the orally administered small molecule inhibitor of DNA repair could potentially be used for the treatment of lung cancer.
Shares gained 7.6%, or $0.19, to $2.69 at 10 a.m. ET. For detailed price information and recent news stories about Spectrum Pharmaceuticals, click SPPI.
For access to the full article, you must be a registered member - it's FREE.
Already a member? Please log in below
Not Registered?
Register today and enjoy all that SmallCapInvestor.com has to offer, including:
- Daily small cap stock profiles.
- Intra-day coverage of Russell 2000 companies.
- Research and insights from our analysts.
- Special reports.
